Beam Therapeutics provided an update on its CRISPR-based therapy designed to treat a rare genetic disease through precise base editing technology. The company's approach uses a specialized form of CRISPR to correct single genetic mutations responsible for the condition.
Base editing represents an advanced gene editing technique that can make precise changes to individual DNA letters without creating double-strand breaks in the genetic code. This method could potentially offer more targeted treatment options for patients with single-gene disorders.